The lawsuit centers on allegations that Capricor Therapeutics withheld critical information regarding the development of Deramiocel, its cell therapy for Duchenne muscular dystrophy. Plaintiffs claim the company modified its pre-specified statistical analysis plan without securing prior FDA approval. This omission allegedly created a significant regulatory hurdle, as the FDA later questioned whether the provided clinical data offered substantial evidence of the treatment's effectiveness.

Defendants are accused of issuing materially misleading statements about the firm's business operations and the prospects for regulatory approval of Deramiocel. Investors who purchased stock during the designated class period may be eligible for compensation. While the litigation is ongoing, no class has been certified, meaning investors are not currently represented by counsel unless they choose to retain their own. Those interested in serving as a lead plaintiff must move the court before the September 28 deadline.